1. Home
  2. ENTO vs FRGT Comparison

ENTO vs FRGT Comparison

Compare ENTO & FRGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • FRGT
  • Stock Information
  • Founded
  • ENTO 2014
  • FRGT 2015
  • Country
  • ENTO United States
  • FRGT United States
  • Employees
  • ENTO N/A
  • FRGT N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • FRGT Professional Services
  • Sector
  • ENTO Health Care
  • FRGT Consumer Discretionary
  • Exchange
  • ENTO Nasdaq
  • FRGT Nasdaq
  • Market Cap
  • ENTO 2.9M
  • FRGT 2.9M
  • IPO Year
  • ENTO 2016
  • FRGT N/A
  • Fundamental
  • Price
  • ENTO $0.49
  • FRGT $1.26
  • Analyst Decision
  • ENTO
  • FRGT
  • Analyst Count
  • ENTO 0
  • FRGT 0
  • Target Price
  • ENTO N/A
  • FRGT N/A
  • AVG Volume (30 Days)
  • ENTO 68.7K
  • FRGT 39.8K
  • Earning Date
  • ENTO 11-13-2024
  • FRGT 03-04-2025
  • Dividend Yield
  • ENTO N/A
  • FRGT N/A
  • EPS Growth
  • ENTO N/A
  • FRGT N/A
  • EPS
  • ENTO N/A
  • FRGT N/A
  • Revenue
  • ENTO N/A
  • FRGT $17,567,033.00
  • Revenue This Year
  • ENTO N/A
  • FRGT $144.53
  • Revenue Next Year
  • ENTO N/A
  • FRGT $55.01
  • P/E Ratio
  • ENTO N/A
  • FRGT N/A
  • Revenue Growth
  • ENTO N/A
  • FRGT N/A
  • 52 Week Low
  • ENTO $0.19
  • FRGT $1.17
  • 52 Week High
  • ENTO $9.35
  • FRGT $67.25
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 43.83
  • FRGT 41.19
  • Support Level
  • ENTO $0.45
  • FRGT $1.22
  • Resistance Level
  • ENTO $0.54
  • FRGT $1.36
  • Average True Range (ATR)
  • ENTO 0.06
  • FRGT 0.11
  • MACD
  • ENTO 0.00
  • FRGT 0.01
  • Stochastic Oscillator
  • ENTO 24.31
  • FRGT 27.27

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About FRGT Freight Technologies Inc.

Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.

Share on Social Networks: